ClinicalTrials.gov
ClinicalTrials.gov Menu

HAL-MPE1 First-in-human (HAL-MPE1/0043)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02163018
Recruitment Status : Completed
First Posted : June 13, 2014
Last Update Posted : July 10, 2015
Sponsor:
Information provided by (Responsible Party):
HAL Allergy

Brief Summary:
Currently, there is no effective causal treatment for peanut allergy. A chemically modified, aluminium hydroxide adsorbed peanut extract (HAL-MPE1) for subcutaneous administration has been developed. Results from in vitro and in vivo preclinical studies demonstrate the immunotherapeutic potential of HAL-MPE1. Therefore, a phase I, single-centre clinical trial has been designed to assess the safety and tolerability of HAL-MPE1 in peanut allergic patients.

Condition or disease Intervention/treatment Phase
Peanut Allergy Drug: HAL-MPE1 Drug: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A First-in-human, Randomized, Double Blind, Placebo Controlled, Single-centre Study to Assess the Safety and Tolerability of HAL-MPE1 in Patients With Peanut Allergy
Study Start Date : June 2014
Actual Primary Completion Date : May 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy

Arm Intervention/treatment
Experimental: HAL-MPE1
Subcutaneous administration of increasing doses of HAL-MPE1.
Drug: HAL-MPE1
Subcutaneous administration of increasing doses of HAL-MPE1
Other Name: HAL-MPE1: modified peanut extract

Placebo Comparator: Placebo
Subcutaneous administration of placebo
Drug: Placebo
Subcutaneous administration of increasing doses of placebo
Other Name: HAL-MPE1 placebo




Primary Outcome Measures :
  1. Safety of a SCIT-treatment with HAL-MPE1 in patients with peanut allergy. [ Time Frame: up to 20 weeks ]
    • Occurrence of early and late local reactions
    • Occurrence of early and late systemic reactions
    • Occurrence of adverse events (clinically relevant abnormalities of the physical examination will be documented as adverse events)
    • Changes in laboratory values, vital signs, ECG and lung function.


Secondary Outcome Measures :
  1. Change in serum levels of allergen specific immunoglobulins [ Time Frame: before and after 15-20 weeks of treatment ]
  2. Change in basophil histamine release test [ Time Frame: before and after 15-20 weeks treatment ]
  3. Change in titrated skin prick test [ Time Frame: before and after 15-20 weeks of treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent.
  2. Male or female subjects aged 18-65 years.
  3. A well-documented medical history of systemic reactions after ingestion of peanut
  4. Positive food challenge at ≤1.5 gram peanut protein ingestion within the last 2 years
  5. Positive serum specific anti-peanut and Ara h 2 Immunoglobulin E (IgE-test) (>0.7 kiloUnits(kU)/L) within the last 2 years
  6. Forced expiratory volume at one second (FEV1)>70% of predicted value

Exclusion Criteria:

  1. Subjects with a history of severe anaphylaxis to peanut with the following symptoms: hypotension, hypoxia, neurological compromise (collapse, loss of consciousness or incontinence) during challenge with peanuts.
  2. Baseline serum tryptase level >20 µg/l
  3. Known allergy or known hypersensitivity to (placebo) excipients
  4. Participation in any interventional study aimed at desensitizing the peanut allergy in the past
  5. Any specific immunotherapy (SCIT, SLIT or OIT) during the study period
  6. Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs
  7. Significant active malignancies or any malignant disease within the past 5 years
  8. Severe uncontrolled diseases that could increase the risk for patients participating in the study, including but not limited to: any severe or unstable lung diseases; endocrine diseases; clinically significant renal or hepatic diseases, or haematological disorders; or severe ongoing symptomatic allergic diseases
  9. History of cardiovascular disease, uncontrolled hypertension or arrhythmias
  10. Diseases with a contraindication for the use of adrenaline (e.g. hyperthyroidism, glaucoma)
  11. Use of systemic steroids within 4 weeks before start of the study and during the study
  12. Treatment with β-blockers/ACE inhibitors
  13. Vaccination within one week before start of therapy or during study
  14. Anti-IgE/anti-Tumor necrosis factor (TNF) therapy or any biologic immunomodulatory therapy within the 6 months prior to inclusion and during the study
  15. Participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study
  16. Pregnancy (test performed at screening), lactation or inadequate contraceptive measures for women of child-bearing age (contraceptive measures considered adequate are: intrauterine devices, hormonal contraceptives, such as contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release)
  17. Alcohol, drug or medication abuse within the past year
  18. Any clinically significant abnormal laboratory parameter at screening
  19. Lack or expected lack of cooperation or compliance
  20. Severe psychiatric, psychological, or neurological disorders
  21. Patients who are employees of the sponsor, institution or 1st grade relatives or partners of the investigators

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02163018


Locations
Denmark
Carsten Bindslev-Jensen
Odense, Denmark, DK 5000
Sponsors and Collaborators
HAL Allergy
Investigators
Principal Investigator: Carsten Bindslev-Jensen, Prof. Dr. Hudafdeling I og Allergicentret, Odense Universitetshospital

Responsible Party: HAL Allergy
ClinicalTrials.gov Identifier: NCT02163018     History of Changes
Other Study ID Numbers: HAL-MPE1/0043
2013-004238-13 ( EudraCT Number )
First Posted: June 13, 2014    Key Record Dates
Last Update Posted: July 10, 2015
Last Verified: July 2015

Additional relevant MeSH terms:
Hypersensitivity
Peanut Hypersensitivity
Immune System Diseases
Food Hypersensitivity
Hypersensitivity, Immediate